REVELATION BIOSCIENCES, INC. (REVB)
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Revelation Biosciences, Inc.
1-25 of 390 filings
Recent SEC filings with analysis
- 8-KRevelation Biosciences reported a Q3 2026 net loss of $3.3 million ($5.92 per share), widening from $1.9 million a year earlier, as operating expenses more…
- 10-QRevelation Biosciences reported a net loss of $9.6 million for the nine months ended September 30, 2026, up from $6.4 million a year ago, with cash of $9.1…